©The Author(s) 2026.
World J Gastroenterol. Feb 7, 2026; 32(5): 113505
Published online Feb 7, 2026. doi: 10.3748/wjg.v32.i5.113505
Published online Feb 7, 2026. doi: 10.3748/wjg.v32.i5.113505
Figure 3 Kaplan-Meier curves for the time to first onset of anti-drug antibodies and drug survival based on initial infliximab clearance.
A: Effect of clearance on time to development of anti-drug antibodies. Black line: Low clearance, orange line: Medium clearance and green line: Fast clearance; B: Effect of use of immunomodulators on time to development of antidrug antibodies. Orange line: Some or no immunomodulator used, black line: No immunomodulator used; C: Effect of clearance on drug survival. Black line: Low clearance, orange line: Medium clearance, green line: Fast clearance.
- Citation: Mould DR, Kutschera M, Primas C, Reinisch S, Novacek G, Lichtenberger C, Dervieux T, Bae Y, Lee SH, Lee JH, Reinisch W. Identification of strong correlations of clearance with clinical outcomes for inflammatory bowel disease. World J Gastroenterol 2026; 32(5): 113505
- URL: https://www.wjgnet.com/1007-9327/full/v32/i5/113505.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i5.113505